Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)

View Full Paper
Ask AI
Bookmark
Share

Authors

ETEkrem TurkDSDavid A. SallmanRKRami S. Komrokji

Discussion

Loading...

Member takes

Overview

Observational analysis shows similar overall survival with intensive chemotherapy and HMA/venetoclax in DDX41-mutated AML, suggesting viable treatment options.

Key Points

  • Overall survival does not significantly differ between treatment with hypomethylating agent/venetoclax and intensive chemotherapy for DDX41-mutated AML.
  • Most common co-mutations in AML patients included TP53, notably affecting prognosis wherever observed.
  • Kaplan-Meier analysis revealed no significant difference in relapse-free survival between the two treatment groups during follow-up.
  • Allogeneic hematopoietic cell transplantation was associated with improved overall survival in the patient cohort evaluated for DDX41 mutations.

Cite This Study

Turk et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6fbhttps://doi.org/10.1182/blood-2025-291
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Decoding DDX41: Clinical impact of germline and somatic mutations in 77 high-risk myeloid neoplasm patients2025 · 1 citations
  2. 2A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium2025
  3. 3Treatment responses and survival of newly diagnosed older or unfit patients (pts) with IDH1/2-mutated Acute Myeloid Leukemia (AML): An analysis of the MARROW consortium2025
  4. 4IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent2025
  5. 5Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study2025